Cel-Sci Corporation

CVM Healthcare Biotechnology

EPS
+65.4%
Free cash flow
−2.33%
Total debt
−39.7%

Quarter to June 2026, against a year earlier

1.45 0.08 +5.84%
Market cap
$24.1M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.63
Beneish M
−2.35
Dividend safety
n/a
Sep '16 Sep '17 Sep '18 Sep '19 Sep '20 Sep '21 Sep '22 Sep '23 Sep '24 Sep '25
Piotroski F-Score
— — — — 4 — — — — —
P/E ratio
0.00 — 0.00 0.00 0.00 — — — — —
P/S ratio
132.11 — 151.86 601.79 838.14 — — — — —
Altman Z-Score
(18.23) — (16.06) (12.60) (1.63) — — — — —
Altman Z″-Score (non-manufacturers)
(43.42) — (39.86) (44.81) (32.34) — — — — —
P/FCF ratio
0.00 — 0.00 0.00 0.00 — — — — —
Beneish M-Score
7.88 — — (3.55) (2.35) — — — — —
P/Operating CF
(5.49) — (17.05) (71.63) (130.57) — — — — —
P/B ratio
0.00 — 80,420.89 54.24 23.74 — — — — —
EV/Sales
171.39 — 160.62 615.12 833.33 — — — — —
EV/EBITDA
0.00 — 0.00 0.00 0.00 — — — — —
EV/FCF
(2.11) — (5.69) (17.09) (25.91) — — — — —
Current Ratio
1.36 0.39 1.24 3.25 4.15 11.50 5.45 1.24 1.31 2.26
Net Debt/EBITDA
(0.44) (0.55) (0.22) (0.26) 0.14 0.85 0.34 (0.21) (0.14) 0.25
Debt/Equity
(19.16) (3.96) 14,866.67 2.63 0.60 0.23 0.36 0.75 0.62 0.36
ROE
423.14% 718.45% 1,909.51% (862.17%) (243.58%) (96.28%) (84.85%) (142.65%) (211.49%) (176.32%)
ROA
(43.09%) (60.35%) (121.31%) (77.38%) (88.84%) (63.08%) (59.54%) (79.86%) (95.90%) (92.16%)
ROIC
(157.00%) (178.26%) (341.36%) (123.78%) (113.43%) (82.04%) (106.25%) (103.44%) (102.38%) (145.08%)
Return on Tangible Assets
(61.25%) (141.64%) (172.82%) (97.85%) (157.07%) (66.75%) (115.21%) (280.94%) (288.20%) (202.56%)
Average Days of Receivables
505.06 0.00 90.91 49.53 35.87 0.00 — — — —
Earnings Yield
(29.06%) — (44.64%) (7.61%) (6.44%) — — — — —
Free Cash Flow Yield
(61.42%) — (18.58%) (5.98%) (3.84%) — — — — —
Free Cash Flow per Share
(142.70) (52.55) (23.75) (16.05) (14.68) (20.55) (13.15) (15.68) (10.50) (4.23)
Book value per Share
(4.19) (12.70) 0.00 4.95 16.12 41.75 22.38 8.92 7.14 3.93
Free Cash Flow
(23.12) (13.81) (13.45) (16.66) (17.97) (27.83) (18.90) (23.22) (18.92) (17.16)
EV/EBIT
0.00 — 0.00 0.00 0.00 — — — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026